Percutaneous Epicardial LAA Closure: When Does it Make Sense?
|
|
|
- Brice Whitehead
- 5 years ago
- Views:
Transcription
1 Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia
2 Disclosures Grant support: Boston-Scientific Inc, Coherex /Biosense-Webster Inc, Sentreheart Inc Grant support / Consultant: St Jude Medical Inc
3 LAA Anatomy
4 Thrombus Formation (TEE)
5 Surgical LAA Exclusion LAA ligation or exclusion is regular part of mitral valve surgery. 1,2 Long term follow-up: Results of MAZE procedure 2 indicate significant reduction of strokes/tia in the case of concomitant LAA closure/exclusion Complete ligation is critical: Katz et al documeted during TEE incomplete LAA closure in 18/50 (36%) patients. 1 Authors indicate residual communication between LAA and rest of LA as increase risk for thromboembolic events. 1 1.Katz et al. Surgical LAA Ligation if Frequently Incomplete: A transesophageal Echocardiographic Study. J AM Coll Cardiol 2000;36: Ad N, Cox JL.. Stroke prevention as an indication for the Maze procedure in the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000.
6 Surgical LAA Incomplete Closure
7 LAA clip occlusion device Atriclip Atricure: Self-closing implantable clip LAA closure regardless of LAA anatomy CT before and at 3-year follow-up after implantation Emmert MY at al: Eur J Cardio-Thorac Surg 2014,45:127.
8 LAA clip occlusion device Emmert MY at al: Eur J Cardio-Thorac Surg 2014,45:127.
9 Stroke Prophylaxis: Alternatives to Drugs Novel Anticoagulants Thrombin Inhibitors Dabigatran Factor Xa Inhibitors Apixaban Rivaroxaban Edoxaban LA Appendage Closure Surgical Epicardial Vascular PLAATO Amplatzer Cardiac Plug Wavecrest Watchman Blackshear and Odell, Ann Thoracic Surgery 1996
10 PLAATO LAA Occlusion Homolka Experience Watchman Amplatzer Cardiac Plug [ACP] WaveCrest Coherex Watchman Flex Watchman Gen 3 Lariat endo/epi Amplatzer Amulet
11 LAA Occlusion Homolka Experience 60 CHADS 2, Ø=2.79 Coherex; Lariat Total 239 implants Amulet W 35% CHA 2 DS 2 VASc, Ø= 3.84 ACP PLAATO M 65% Watchman Other Occluder Watchman Age in time of procedure Age < 37 Age > 89 Average 71.4 First half 68 Second half 74 Younger > 50 years 3 Registr OLAA NNH, 2015
12 PLAATO: Long-Term Outcomes 23 pts followed for 58 ± 9 mos Age: 68 ± 5 years CHADS 2 score: 3.6 ± 0.6 Hx CVA/TIA: All pts Long-Term follow-up: 58 ± 9 mos 2 deaths: cancer and CHF 4/23 (3.4%/yr) with CVA/TIA Time-to-event: 29.7 ± 10 mos All recovered w/o major sequelae CT/TEE: Leaks in 3/4 pts (75%) Do leaks predict strokes? LAA LEAK PLAATO With Stroke/ TIA Without Stroke/ TIA Age 61.8 ± ± 5.7 CHADS ± ± 0.5 Leak? 3/4 (75%) 7/9 (78%) P.Neuzil & V.Reddy, JICE, 2012
13 Do peri-device leaks portend worse prognosis? Leak at 12mo in Primary Event Rate PROTECT AF (Events / 100 pt-yrs) cohort No Leak 67,9% 67.9% 2,5 2.5 Leak ( 5 mm) 32,1% 32.1% 2,1 2.1 J.Viles-Gonzales / V.Reddy, JACC
14 Epicardial LAA Ligation Electrocardiogram Guided Approach A B Friedman PA at al: J Cardiovasc Electrophysiol, 2009, 20: 909.
15 Stroke Prophylaxis: LAA Epicardial Exclusion Novel Anticoagulants Thrombin Inhibitors Dabigatran (RELY) Factor Xa Inhibitors Apixaban (AVERROES) Rivaroxaban (ROCKET AF) Sternum RV Liver LV LA Appendage Closure Surgical Epicardial Vascular PLAATO Amplatzer Cardiac Plug Wavecrest Watchman Modified from slide from: E Sosa, M Scanavacca, A d Avila
16 Lariat Epicardial LAA Ligation Components Bartus K at al: JACC 2013, 62:
17 Lariat Epicardial LAA Ligation Os Landmark Proximal LAA Closure
18 Lariat Epicardial LAA Ligation Melzer Knot Pre-confirm Control of Suture Atraumatic Suture Release
19 LAA Suture Ligation: Pre-Clinical Work Endocardial Balloon: Not Used Residual LAA Remnant: 3 / 4 (75%) S.Singh / A.d Avila / S.Dukkipati / V.Reddy, Heart Rhythm 2010
20 LAA Suture Ligation: Pre-Clinical Work Endocardial Balloon: Used Residual LAA Remnant: 0 / 5 (0%) S.Singh / A.d Avila / S.Dukkipati / V.Reddy, Heart Rhythm 2010
21 Clinical LAA Suture Ligation
22 Clinical LAA Suture Ligation
23 Clinical LAA Suture Ligation
24 Clinical LAA Suture Ligation Pre-Ligation Post-Ligation LAA
25 Lariat Incomplete LAA Suture Di Biase at al: Heart Rhythm 2014,11:
26 LARIAT Epicardial LAA Ligation multicenter clinical experiences Study included 41 patients (4 centers) - LAA closure with the LARIAT system. RESULTS Ø age was 75 ± 10 years, Ø mean CHADS 2 score was 3.0 ± 1.3, Ø HAS-BLED score was 4.4 ± 1.4. Accumulated 24.6 person-years of follow-up. Acute LAA closure was achieved in 38 patients (93 %). 3.3 ± 0.8 m. after the procedure LAA leakage demonstrated by TEE or CT in 24 % pts. 1 pt (2 %) TIA, 8 (20 %) pericardial effusions requiring pericardiocentesis. 4 (9 %) were complicated by perforation of the LAA, with 2 of these patients requiring open surgical correction. Miller MA at al: Heart Rhythm 2014, 11:
27 LARIAT Epicardial LAA Ligation multicenter clinical experiences Anticoagulation/Antiplatelet therapy pre and post Lariat Miller MA at al: Heart Rhythm 2014, 11:
28 LARIAT Epicardial LAA Ligation first clinical experiences Single center non-randomized trial 85/89 (96%) patients IMPL/INCL 81 pts complete closure immediatelly 3 pts >2 mm residual leak 1 pt >3 mm residual leak At 1+3 months 81/ /81 (95%) complete closure After 1 year 65 (98%) complete closure included 1 with previous leak COMPLICATIONS: Access related 3, pericardial effussion 2 / late 1, SCD 2, late stroke 2 Bartus K at al: JACC 2013, 62:
29 LARIAT Epicardial LAA Ligation first clinical experiences Bartus K at al: JACC 2013, 62:
30 LARIAT Epicardial LAA Ligation first clinical experiences 3D CT reconstruction Bartus K at al: JACC 2013, 62:
31 LARIAT Epicardial LAA Ligation first clinical experiences Fluoroscopic guidance to assist in the closure of the LAA Bartus K at al: JACC 2013, 62:
32 LARIAT Epicardial LAA Ligation first clinical experiences Bartus K at al: JACC 2013, 62:
33 LARIAT Epicardial LAA Ligation first clinical experiences Pericardial access approach Bartus K at al: JACC 2013, 62:
34 LARIAT Epicardial LAA Ligation Intraoperative Multimodality Imaging TEE guidance of LARIAT balloon placement Laura DM at al: JASE 2014, 27:704.
35 LARIAT Epicardial LAA Ligation Intraoperative Multimodality Imaging Fluoroscopy guidance of wires connection and snare placement Laura DM at al: JASE 2014, 27:704.
36 ? Price M J at al: JACC 2014, 64: 569.
37 FINAL THOUGHTS 1. Epicardial LAA exclusion is more independent on its anatomy 2. There is no any device implanted 3. Stop anticoagulation after procedure 4. Less thrombogenic 5. Permanent occlusion?
38
39 Computed tomography findings at twelve-, twenty-, and thirty-six month follow-up after LAA clip surgery Emmert MY at al: LAA clip occlusion device. Eur J Cardio-Thorac Surg 2014,45:129.
40 Adverse events after LAA closure using the LARIAT device Miller MA at al: Safety of LAA closure with the LARIAT device. Heart Rhythm 2014, 11:1856.
41 Percutaneous Appendage Closure. Background: Pharmacologic therapies to prevent stroke in atrial fibrillation (AF) have numerous limitations, prompting the development of device-based therapies. We investigated whether an electrogram-based approach using a novel hollow suture can safely capture and ligate the left atrial appendage (LAA). Methods and Results: A novel system for closure of the LAA within the confines of the closed pericardium with a single sheath puncture was tested in 4 dogs. The tool used to grasp the appendage was fitted with electrodes and utilized electrical navigation to identify and confirmlaacapture. Ahollowsuture preloaded with a mechanical support wire to permit its manipulation and fluoroscopic visualization was advanced over the grasper, and the wire removed after the suture was positioned. The LAA was successfully closed in all dogs. In 2 dogs, after closure, a thoracotomy was performed and the LAA amputated without bleeding, confirming closure integrity. Necropsy confirmed closure in all animals. Conclusions: Using electrical navigation, percutaneous epicardial LAA ligation with a remotely tightened suture was performed successfully within the confines of the intact pericardial space. This technique may allow decreasing the risk of stroke in AF patients without the need for thoracotomy or an endocardially placed prosthetic device. left atrial appendage, atrial fibrillation, stroke, epicardial, electrograms Friedman PA at al.:percutaneous appendage closure. J Cardiovasc Electrophysiol, 2009,, 20, :
42 Necropsy evaluation of left atrial appendage (LAA closure) Friedman PA at al: Percutaneous appendage closure. J Cardiovasc Electrophysiol, 2009, 20: 913.
Devices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
Appendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
Role of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
Left Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES Dr. Marco Barbierato Interventional Cardiology Cardio-Thoraco-Vascular Department
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
Update in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
Modern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
ICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
Left atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure. Miguel Valderrábano, MD
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure Miguel Valderrábano, MD Risk of Stroke in Atrial Fibrillation CHADS 2 -CHA 2 DS 2 -VASc Scores Adjusted
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
NCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
Left Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
Left Atrial Appendage Closure Techniques: 2015
Left Atrial Appendage Closure Techniques: 2015 Ramon Quesada, MD, FACP, FACC, FSCAI Medical Director, Interventional Cardiology & Cardiac Research Medical Director, Structural Heart and TAVR Program Baptist
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
Update in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
Left Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
Atrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
Europe. Other LAA occlusion devices are in clinical development.
EXPERT REVIEW INTERVENTIONS FOR STRUCTURAL HEART DISEASE Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: rationale, devices in clinical development and insights
Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
Clinical Policy Bulletin: Cardiac Devices and Procedures for Occlusion of the Left Atrial Appendage
Close Window Enter CPB Search Term: Go Clinical Policy Bulletin: Cardiac Devices and Procedures for Occlusion of the Left Atrial Appendage Number: 0791 Policy *Please see amendment for Pennsylvania Medicaid
Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
Devices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
Left Atrial Appendage Closure: The Good, The Bad and The Ugly
Left Atrial Appendage Closure: The Good, The Bad and The Ugly John D. Hummel, MD Director of Electrophysiology Research Ross Heart Hospital, The Ohio State University Columbus, Ohio USA Disclosures Modest
Left Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
Recurrent Stroke under Anticoagulation in Mild MS & AF
Recurrent Stroke under Anticoagulation in Mild MS & AF - Minimal maze operation and LAA excision or exclusion- Seung Hyun Lee, M.D, Ph.D Division of Thoracic and Cardiovascular surgery Severance cardiovascular
Atrial fibrillation (AF) remains the most common
The Spectrum of Devices for Percutaneous Left Atrial Appendage Occlusion A look at current and emerging nonpharmacologic stroke prevention therapies. BY LLUIS ASMARATS, MD, AND JOSEP RODÉS-CABAU, MD Atrial
Clinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device
Clinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device The clinical data used to support the CE marking of the Ultraseal LAA Closure device comes from three sources.
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Medicine
Disclosures 6/16/2015. Preventing Stroke in Atrial Fibrillation Warfarin Intolerance / Non-Compliance
6/16/2015 Data Behind LAA Closure This is Ready for Prime Time! Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia Service The Mount Sinai Hospital vivek.reddy@mountsinai.org
EP Clinical Research Program Summary. Daniel L Lustgarten MD PhD Associate Professor The University of Vermont School of Medicine
EP Clinical Research Program Summary Daniel L Lustgarten MD PhD Associate Professor The University of Vermont School of Medicine Financial Disclosures Consultant and/or Research Support: Medtronic Biosense
Update in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
THINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure with Transeosophageal Echocardiography Guidance
Hindawi Publishing Corporation rombosis Volume 2014, Article ID 832752, 6 pages http://dx.doi.org/10.1155/2014/832752 Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure
Medical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
Hands on workshops. 08:00-10:15 Session 1 - LAA morphology and imaging Moderator: Saibal Kar, MD / Shakeel A. Qureshi, MD / Bushra Rana, MD
Friday, November 20th, 2015 07:00-18:30 Registration 07:00-08:00 Welcome coffee Hands on workshops 08:00-10:15 Session 1 - LAA morphology and imaging Moderator: Saibal Kar, MD / Shakeel A. Qureshi, MD
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
Exclusion de l auricule gauche par voie percutanée
Exclusion de l auricule gauche par voie percutanée Jean-Michel Juliard, Dominique Himbert, Pierre Aubry, Eric Brochet, Alec Vahanian Hôpital Bichat, Paris Pas de conflit d intérêt 2012 The Left Atrial
Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
Patients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
MEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
Commercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
Left Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation
Received: 15 May 2017 Revised: 21 June 2017 Accepted: 26 June 2017 DOI: 10.1002/clc.22764 REVIEWS Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation Rizma Jalees
Which System Is better?: Watchman or Cardiac Plug or Something Else?
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 Which System Is better?: Watchman or Cardiac Plug or Something Else? Horst Sievert, Annkathrin Brauth, Isabel Schulmeyer, Patrick Boehm, Jonas
THINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
Modern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
Rate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
Scientific Program of LAA 2014
Scientific Program of LAA 2014 Friday, November 14th, 2014 08:00-18:30 Registration 08:00-08:05 Welcome 08:05-08:45 Session 1: How Morphology Affects Short- and Long-term Outcome? What you Need to Know
Non-Pharmacologic Stroke Prevention For Atrial fibrillation: A Practical Review for the Practicing Cardiologist
Review articles A Journal of Cardiological Society of India, Kerala Chapter Non-Pharmacologic Stroke Prevention For Atrial fibrillation: A Practical Review for the Practicing Cardiologist a b c Srinivasa
Updates in Atrial Fibrillation
Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
Cryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
THINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
LAA and Stroke Prevention
LAA and Stroke Prevention Samuel J. Asirvatham, MD Professor of Medicine, Professor of Pediatrics Program Director Cardiac Electrophysiology; Vice Chair Innovations Mayo Clinic Turin, October 26, 2012
Cardiac Devices Past, Present, and Future. Outline
Cardiac Devices Past, Present, and Future Charles Henrikson, MD Director, Electrophysiology Service 11 September 2016 Outline Introduction Native conduction system Indications for PPMs Indications for
Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine
2.02.26 Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine Effective Date August 29, 2014 Subsection Cardiology Original Policy Date July 6,
Left Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 12/2018 Origination: 1/2012 Next Review: 12/2019 Policy Blue Cross and
Left Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 6/2014 Origination: 1/2012 Next Review: 12/2014 Policy Blue Cross and
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
Incomplete surgical ligation of the left atrial appendage time for a new look at an old problem
Editorial Page 1 of 5 Incomplete surgical ligation of the left atrial appendage time for a new look at an old problem Arash Aryana, Rohit Bhaskar Mercy General Hospital and Dignity Health Heart and Vascular
Relevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
16th ANGIOPLASTY SUMMIT-TCTAP TCTAP 2011 Seoul, Korea, April 27 29, 2011 Left Atrial Appendage Closure State of the Art Horst Sievert, Nina Wunderlich, Maik Gonzaga, Annkathrin Braut, Ilona Hofmann CardioVascular
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
Atrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
Five years of keeping a watch on the left atrial appendage how has the WATCHMAN fared?
Perspective Five years of keeping a watch on the left atrial appendage how has the WATCHMAN fared? Mohammad-Ali Jazayeri, Venkat Vuddanda, Valay Parikh, Madhav Lavu, Donita Atkins, Y. Madhu Reddy, Jayant
Technique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
Managing the Left Atrial Appendage: Concepts & Controversies
Managing the Left Atrial Appendage: Concepts & Controversies SH-102103-AD- APR 2013 Carlos A. Morillo, MD, FRCPC, FACC, FHRS, FESC Professor Department of Cardiac Sciences Section Chief Cardiology Division,
More than 6 million people worldwide suffer from atrial
Catheter-Based Left Atrial Appendage (LAA) Ligation for the Prevention of Embolic Events Arising From the LAA Initial Experience in a Canine Model Randall J. Lee, MD, PhD; Krzysztof Bartus, MD; Steven
NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION
NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION MAY 1, 2015 Melissa R. Robinson, MD FACC FHRS CCDS Assistant Professor of Medicine Director of the Complex Arrhythmia Service POINTS TO MAKE
ESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
Chapter 76 Left Atrial Appendage Closure: Indication and Technique
Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
Structural Heart Disease:" Innovations in Intervention!
Structural Heart Disease:" Innovations in Intervention! Jon C. George, MD, FACC, FSCAI! Director, Clinical Research! Assistant Director, Cardiac Catheterization Lab! Deborah Heart and Lung Center! Aortic
Percutaneous Transvenous Atrial Fibrillation Ablation and Stroke
Percutaneous Transvenous Atrial Fibrillation Ablation and Stroke Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia Service The Mount Sinai Hospital Disclosures Grant
European Journal of Cardio-Thoracic Surgery Advance Access published May 8, 2013
European Journal of Cardio-Thoracic Surgery Advance Access published May 8, 2013 European Journal of Cardio-Thoracic Surgery (2013) 1 6 doi:10.1093/ejcts/ezt204 ORIGINAL ARTICLE Safe, effective and durable
WATCHMAN: Where do we stand
Latest Updated on LAAC and Its Clinical Evidence Saibal Kar, MD, FACC, FAHA, FSCAI Associate Professor Heart Institute, t Cedars Sinai i Medical Center, Los Angeles, CA Disclosure Information WATCHMAN:
Page 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
Atrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
LAmbre LAA Occluder Updates
LAmbre LAA Occluder Updates 4 th Asia Pacific Congenital & Structural Interventional Symposium 6 th June, 2013 Hong Kong Yat-yin LAM MBBS MRCP FHKCP FHKAM FESC FRCP FACC MD Associate Professor, Prince
Abstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
Show Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION:
PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION: Procedural Experience and Clinical Follow-up with the AMPLATZER Cardiac Plug and AMPLATZER Amulet
The EP Perspective: Should We Do Hybrid Ablation, and Who Should We Do It On?
The EP Perspective: Should We Do Hybrid Ablation, and Who Should We Do It On? L. Pison, MD PhD FESC AATS Surgical Treatment of Arrhythmias and Rhythm Disorders November 17-18, 2017 Miami Beach, FL, USA